Kodiak Sciences Inc Common Stock

Day range

$87.61 – $91.89

Open

$88.03

Prev close

$87.63

Volume

304.06K

Market cap

$5.51B

Shares out

62.85M

P/E

—

P/S

—

P/B

90.14

P/FCF

—

ROE

-396.1%

ROA

-94.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 28, 2026

  On September 28, 2026, Kodiak Sciences Inc. (the "Company") issued a press release announcing that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Company's Phase 3 DAYBREAK study in patients with wet age-related macular degeneration.

• Clinical trial resultsMar 27, 2026

  On March 26, 2026, Kodiak Sciences Inc. (the "Company") issued a press release announcing positive topline results in GLOW2, the Company's second Phase 3 study in diabetic retinopathy, demonstrating superiority of Zenkuda™ (tarcocimab tedromer) over sham.

• Underwriting agreementDec 18, 2025

  On December 16, 2025, Kodiak Sciences Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group L.L.C. and UBS Securities LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the public offering, issuance and sale (the "Offering") of 6,956,522 shares of its common stock.

• Clinical trial resultsNov 6, 2023

  On November 6, 2023, Kodiak announced that its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint. At one year, GLOW met its primary endpoint of the proportion of patients with at least a 2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) score... Tarcocimab achieved a 29-fold increased response rate ratio, with 41.1% of evaluable patients on tarcocimab demonstrating at least 2-step improvement versus 1.4% of evaluable patients in the sham group (p less than 0.0001).

• Executive officer departureAug 17, 2023

  On August 16, 2023, Jason Ehrlich, M.D., Ph.D., informed the Company of his resignation as Chief Medical Officer and Chief Development Officer of the Company, effective August 25, 2023. Dr. Ehrlich's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Days to cover

1.8

Short interest

9.38M

Avg volume

5.21M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
  positiveZacks Investment Research· Sep 29, 2026
• The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
  negativeZacks Investment Research· Sep 23, 2026
• Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development
  positiveGlobeNewswire Inc.· Jul 3, 2026
• Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers
  positiveBenzinga· Apr 17, 2026
• Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday
  positiveBenzinga· Sep 25, 2025